An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Description

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Conditions

Hepatitis B, Hepatitis, Liver Diseases

Study Overview

Study Details

Study overview

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Condition
Hepatitis B
Intervention / Treatment

-

Contacts and Locations

Phoenix

Banner University Medical Center Phoenix, Phoenix, Arizona, United States, 85006

Los Angeles

Asian Pacific Liver Center at Coalition of Inclusive Medicine, Los Angeles, California, United States, 90020

Pasadena

California Liver Research Institute, Pasadena, California, United States, 91105

Redwood City

Stanford University, Redwood City, California, United States, 94063

Sacramento

UC Davis GI/Hepatology Clinical Trials Unit, Sacramento, California, United States, 95817

San Jose

Silicon Valley Research Institute, San Jose, California, United States, 95128

New Haven

Yale University Digestive Diseases, New Haven, Connecticut, United States, 06520

Washington

Medstar Georgetown University Hospital, Washington, District of Columbia, United States, 20007

Gainesville

University of Florida, Gainesville, Florida, United States, 32610-0272

Miami

University of Miami, Schiff Center for Liver Disease, Miami, Florida, United States, 33136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Target PharmaSolutions, Inc.,

    Study Record Dates

    2026-01